Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice.
Anemia
/ etiology
Animals
Antineoplastic Agents
/ adverse effects
Blood Cell Count
Breast Neoplasms
/ drug therapy
Cyclophosphamide
/ adverse effects
Disease Models, Animal
Docetaxel
/ adverse effects
Doxorubicin
/ adverse effects
Drug Therapy, Combination
Female
Fluorouracil
/ adverse effects
Leukopenia
/ etiology
Melatonin
/ administration & dosage
Mice
Mice, Transgenic
Receptor, ErbB-2
/ metabolism
Chemotherapy
Circadian time
Mammary adenocarcinoma
Melatonin
Mice
Journal
Chemotherapy
ISSN: 1421-9794
Titre abrégé: Chemotherapy
Pays: Switzerland
ID NLM: 0144731
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
11
2019
accepted:
08
06
2020
pubmed:
11
8
2020
medline:
4
5
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
The effects of chemotherapy are known to depend on the time of administration. Circadian rhythms are disturbed in tumors and in tumor bearers. Agents involved in controlling the circadian rhythms (chronobiotics) potentially can modify the outcomes of chemotherapeutics administered at different times of the day. Pineal hormone melatonin (MT) is a prototypic chronobiotic. The aim of the study was to investigate if MT can affect efficacy or toxicity of chemotherapy drugs administered at the extreme time points of the working day of hospital personnel. Cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and adriamycin and docetaxel (AT) cytotoxic drug combinations were administered on day 0 at 11:00 a.m. or at 5:00 p.m. (UTC+03:00) to 6-month-old female HER2/neu transgenic FVB/N mice bearing mammary adenocarcinomas. Some mice were additionally provided with MT in drinking water (20 mg/L) at night 1 week before or 3 weeks after treatment or during both periods. Tumor node sizes, body weight, and blood cell counts were determined right before treatment and on days 2, 7, 14, and 21. Significant decrease in the mean tumor node volume was found by days 14 and 21 upon all CAF and AT treatment schedules, except in animals treated with AT at 5:00 p.m. without supplementation with MT. In the latter case, mean tumor node volume on day 21 was the same as in the control. Supplementation of AT administered at 5:00 p.m. with MT improved the tumor response. CAF and AT regimens supplemented with MT also augmented the number of tumor nodes that did not increase by more than 20% by day 21 as compared to CAF or AT alone, respectively. This effect was significant in groups treated with AT at 5:00 p.m. and consistent upon other schedules. On day 7, leukopenia and anemia were registered in groups treated with CAF regimen; however, blood cell counts normalized by day 14. Both CAF and AT were associated with drop in the body weight registered on day 7. Supplementation with MT did not affect changes of the body weight and blood counts. MT supplementation to cytotoxic drugs can improve antitumor response, especially if it is blunted because of an inappropriate time of administration.
Identifiants
pubmed: 32772021
pii: 000509238
doi: 10.1159/000509238
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Receptor, ErbB-2
EC 2.7.10.1
Melatonin
JL5DK93RCL
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-50Informations de copyright
© 2020 S. Karger AG, Basel.